Natera’s Signatera Shows High Sensitivity in Radiation Oncology Studies
Event summary
- Natera presented four oral abstracts at ASTRO 2026, its first participation in the conference.
- Signatera demonstrated 100% sensitivity in detecting local cancer growth or recurrence in rectal cancer.
- In anal squamous cell carcinoma, Signatera positivity post-chemoradiation correlated with 8% 18-month PFS.
- Studies in gynecological cancers showed Signatera’s ability to predict recurrence up to 117 days before radiographic detection.
The big picture
Natera’s ASTRO 2026 presentations underscore the growing role of circulating tumor DNA (ctDNA) in radiation oncology, particularly for risk stratification and early recurrence detection. The data positions Signatera as a potential standard-of-care tool, though its long-term adoption will depend on payer acceptance and competitive differentiation in the precision oncology space.
What we're watching
- Clinical Adoption
- How quickly radiation oncologists integrate Signatera into standard treatment protocols.
- Competitive Positioning
- Whether Natera can sustain its lead in ctDNA monitoring amid growing competition.
- Regulatory Pathways
- The pace at which ASTRO data translates into expanded reimbursement coverage.
Related topics